We found that ICBs increased CD39, an ectonucleotidase involved in the conversion of ATP to immunosuppressive adenosine [38, 39], on B16F10 melanoma cells but this effect was efficiently counteracted by guadecitabine. Here, ENTPD1 is linked to melanoma.